Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1BRWD)

Drug Name
Concizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Haemophilia A 3B10.0 Phase 3 [1]
Haemophilia B 3B11.0 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM1BRWD

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tissue factor pathway inhibitor (TFPI) TT068JH TFPI1_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tissue factor pathway inhibitor (TFPI) DTT TFPI 6.785 5.293 7.315 5.975
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Haemophilia A
ICD Disease Classification 3B10.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tissue factor pathway inhibitor (TFPI) DTT TFPI 1.27E-08 0.14 0.84
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05135559) Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors. U.S.National Institutes of Health.
2 Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 Nov 28;134(22):1973-1982.